In an op-ed, Professor Melissa Schilling points to the negative consequences of generic drug substitution
— June 23, 2015
Excerpt from CNBC -- "There are two big problems with the current automatic substitution system. First, generics are not identical to the branded drug. Generic drugs only have to meet the standard of 80 percent to 125 percent of the bioavailability of the referenced drug ... The second problem with automatic substitution is that it forces branded companies to subsidize generics, undermining competition and innovation ... We should instead be looking for ways to make clinical testing more efficient, and generally lowering the entry barriers to competition among branded pharmaceutical companies."